Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine is a synthetic small molecule belonging to the imidazopyridine class of organic compounds. It is a heterocyclic compound with the molecular formula C12H11ClN6 and an average molecular weight of approximately 274.71 g/mol. The compound has been studied experimentally but has not been approved for any therapeutic use or entered clinical trials beyond preclinical investigation. Its mechanism of action is not well characterized in public sources; however, it may have potential as a research tool or chemical probe targeting protein-protein interactions such as those involving the AKT1 (RAC-alpha serine/threonine-protein kinase) pathway based on limited functional annotations.[1][2][3][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine.